Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
NCT ID: NCT01146535
Last Updated: 2013-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2011-01-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interferon-alpha
Interferon-alpha
150 IU lozenges bid for 5 days
Interferon-alpha
150 IU lozenges bid for 5 days
Oseltamivir
75 mg capsules bid for 5 days
maltose
maltose
200 mg maltose lozenges bid for 5 days
Oseltamivir
75 mg capsules bid for 5 days
maltose
200 mg maltose lozenges bid for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon-alpha
150 IU lozenges bid for 5 days
Oseltamivir
75 mg capsules bid for 5 days
maltose
200 mg maltose lozenges bid for 5 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* one or more respiratory symptoms (e.g. cough, rhinorrhea or sore throat) plus one or more constitutional symptoms (e.g. chills, headache, malaise and myalgias)of \< 48 hours' duration
* body weight \> 40 kg
* positive for influenza A (nasal swab rapid test)
Exclusion Criteria
* history of depression or psychiatric disorders
* history of conditions that could complicate flu infection, such as chronic pulmonary, cardiac, renal, or metabolic disorders
* use of immunosuppressive therapy
* HIV infection
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CytoPharm, Inc.
INDUSTRY
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chang Gung Medical Foundation, LinKou Branch
Guishan, Taoyuan County, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Zuoying District, Taiwan
Show-Chwan Memorial Hospital
Changhua, , Taiwan
Taiwan Municipal Hospital
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QCR09025
Identifier Type: -
Identifier Source: org_study_id